8-K: Immunovant's Batoclimab Shows Durable Graves Disease Remission

Immunovant announced positive six-month off-treatment data for batoclimab in Graves disease, demonstrating durable response and anti-thyroid drug-free remission.

Summary

• Batoclimab's proof-of-concept study in uncontrolled Graves disease patients demonstrated strong durability of response and anti-thyroid drug (ATD)-free remission.
• Of 21 patients who entered the six-month off-treatment follow-up period, approximately 80% (17/21) maintained normal thyroid function (T3 and T4 less than the upper limit of normal) at Week 48.
• Approximately 50% (8/17) of these responders achieved ATD-free remission at six months following the end of batoclimab treatment.
• An additional 30% (5/17) of responders were on low ATD doses (2.5 mg/day) after six months off-treatment, even with a suboptimal step-down dosing design during the treatment period.
• Safety and tolerability of batoclimab were consistent with prior studies, with no new safety signals identified.
• Two potentially registrational global trials for IMVT-1402, Immunovant's lead compound, in Graves disease are currently enrolling, with topline readouts expected in 2027.
• The IMVT-1402 registrational trials will evaluate a continuous 600 mg dose for up to 52 weeks, an optimization based on batoclimab's Phase 2 learnings, aiming for improved efficacy.

Sentiment

Score: 9

Explanation: The clinical data for batoclimab in Graves disease are exceptionally positive, demonstrating strong durability and a high rate of ATD-free remission, suggesting potential disease modification. This addresses a significant unmet medical need and positions IMVT-1402 for potentially transformative registrational trials. The only minor detraction is the standard boilerplate risks associated with clinical development.

Positives

• Approximately 80% (17/21) of patients maintained normal thyroid function six months after discontinuing batoclimab treatment, indicating strong durability of response.
• Approximately 50% (8/17) of responders achieved anti-thyroid drug (ATD)-free remission, demonstrating potential for disease modification.
• Batoclimab was well-tolerated with no new safety signals identified, and all treatment-related adverse events were mild or moderate.
• Sustained reductions in Thyrotropin Receptor Autoantibodies (TRAb) post-batoclimab treatment further support the potential for disease modification.
• The design of the IMVT-1402 registrational trials is optimized with a continuous high dose (600 mg QW SC for up to 52 weeks), which could lead to improved efficacy data compared to the batoclimab step-down dosing.

Risks

• Initial results or preliminary analyses of early clinical trials may not be predictive of final trial results or results of later clinical trials.
• Results of animal studies may not be predictive of results in humans.
• The timing and availability of data from clinical trials, discussions with regulatory agencies, and potential approvals are uncertain.
• Future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed.
• Any product candidate developed may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.
• Product candidates may not be beneficial to patients, or even if approved, may not be successfully commercialized.
• Global factors such as geopolitical tensions and adverse macroeconomic conditions could affect business operations and supply chains, including clinical development plans and timelines.
• Immunovant's business is heavily dependent on the successful development, regulatory approval, and commercialization of batoclimab and IMVT-1402.
• Immunovant will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development.

Future Outlook

Immunovant anticipates that IMVT-1402 could be the first-in-class disease-modifying therapy for Graves disease, addressing a significant unmet need. The ongoing registrational trials for IMVT-1402 are designed to potentially generate improved efficacy data due to continuous high-dose administration, with topline results expected in 2027. The company expects these advancements to transform the treatment paradigm for uncontrolled Graves disease patients.

Management Comments

• George Kahaly, M.D., Ph.D., Lead Principal Investigator, stated: 'These novel and encouraging results support FcRn blockade as a potentially effective mechanism for the treatment of Graves disease, with the six-month remission data providing evidence of potential disease modification.'
• Eric Venker, M.D., Pharm.D., CEO of Immunovant, commented: 'We are incredibly excited to present these remission data demonstrating strong durability of response and ATD-free remission in previously uncontrolled patients off-treatment for six months. We believe these data have the potential to be transformative for patients and practice-changing for physicians, if approved by FDA, by addressing a significant unmet need in Graves disease.'

Industry Context

Graves disease is a classic autoimmune condition driven by autoantibodies, affecting a significant patient population where 25-30% remain relapsed, uncontrolled, or intolerant to existing anti-thyroid drugs (ATDs). These patients face a higher risk of severe comorbidities like cardiovascular events, thyroid eye disease (TED), and thyroid storm. There is a high unmet need for disease-modifying therapies, as current ablative options are often avoided. Immunovant's FcRn blockade approach with batoclimab and IMVT-1402 represents a potential paradigm shift by addressing the underlying disease pathology, offering a novel therapeutic option in a market lacking such innovation.

Comparison to Industry Standards

• The observed six-month off-treatment ATD-free remission in uncontrolled Graves disease patients with batoclimab represents a significant advancement, as it is described as the 'first-ever potentially disease-modifying therapy' for this condition.
• Current standard treatments, primarily ATDs, often lead to relapse or intolerance in 25-30% of patients, and ablative options are often not preferred, leaving a substantial unmet need that this therapy aims to address.
• Unlike existing therapies that manage symptoms, batoclimab's mechanism of FcRn blockade and sustained TRAb reductions suggest a more fundamental impact on the disease, potentially offering a long-term solution for patients who currently lack effective alternatives.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong clinical data, potential for a first-in-class disease-modifying therapy, and advancement of a key pipeline asset (IMVT-1402) into registrational trials, which could significantly increase market value.
• **Patients:** Highly positive impact as the therapy offers potential for durable remission and freedom from anti-thyroid drugs, addressing a significant unmet need for those with uncontrolled Graves disease and potentially improving quality of life and reducing comorbidities.
• **Physicians:** Positive impact by providing a novel, potentially disease-modifying treatment option that could change the standard of care for Graves disease, particularly for patients who are unresponsive or intolerant to current therapies.
• **Employees:** Positive impact through the successful progression of clinical programs, potentially leading to increased job security and growth opportunities within a company developing innovative therapies.

Next Steps

• Presentation of six-month off-treatment data at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.
• Host a conference call and webcast to discuss the remission data from the Graves Disease trial on September 3, 2025, at 4:30 p.m. E.D.T.
• Continue enrollment in two potentially registrational global trials for IMVT-1402 in Graves disease.
• Anticipate topline readouts for the IMVT-1402 registrational trials in 2027.

Key Dates

Recommendation

The filing presents highly compelling clinical data for batoclimab in Graves disease, demonstrating durable response and a significant rate of ATD-free remission, which is a strong indicator of disease modification. This represents a substantial breakthrough in an area with high unmet medical need. The ongoing registrational trials for IMVT-1402 are strategically designed to build upon these positive results. Given the transformative potential for patients and the market opportunity, this news is likely to drive significant investor interest and a positive re-rating of the stock, warranting a strong buy recommendation for a seasoned investor.

Keywords

Graves Disease, Immunovant, batoclimab, IMVT-1402, FcRn blockade, autoimmune disease, thyroid disease, clinical trial, remission, FcRn inhibitor